Center-Authored Papers

Filters: Author is Wilbur, D Scott  [Clear All Filters]
2016
Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SHL, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA et al..  2016.  Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B cell cancers.. Cancer research. Abstract
2015
Orozco JJ, Kenoyer A, Balkin ER, Gooley TA, Hamlin DK, Wilbur SD, Hylarides MD, Frost SHL, Mawad R, O'Donnell P et al..  2015.  Anti-CD45 radioimmunotherapy without TBI before BMT facilitates persistent haploidentical donor engraftment in a murine model.. Blood. Abstract
Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur SD, Balkan ER, Lin Y et al..  2015.  Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.. Blood. 125(13):2111-9. Abstract
Miller BW, Frost SHL, Frayo SL, Kenoyer AL, Santos E, Jones JC, Green DJ, Hamlin DK, Wilbur SD, Fisher DR et al..  2015.  Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.. Medical physics. 42(7):4094. Abstract
Frost SHL, Miller BW, Bäck TA, Santos EB, Hamlin DK, Knoblaugh SE, Frayo SL, Kenoyer AL, Storb R, Press OW et al..  2015.  Alpha Imaging Confirmed Efficient Targeting of CD45-Positive Cells after Astatine-211 (211At)-Radioimmunotherapy for Hematopoietic Cell Transplantation.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(11):1766-73. Abstract
Burtner C, Chandrasekaran D, Santos E, Beard B, Adair J, Hamlin D, Wilbur SD, Sandmaier B, Kiem H-P.  2015.  211Astatine-conjugated monoclonal CD45 antibody-based nonmyeloablative conditioning for stem cell gene therapy.. Human gene therapy. Abstract
2014
Balkin ER, Kenoyer A, Orozco JJ, Hernandez A, Shadman M, Fisher DR, Green DJ, Hylarides MD, Press OW, Wilbur SD et al..  2014.  In vivo localization of 90Y and 177Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.. Cancer research. 74(20):5846-54. Abstract
Orozco JJ, Balkin ER, Gooley TA, Kenoyer A, Hamlin DK, Wilbur SD, Fisher DR, Hylarides MD, Shadman M, Green DJ et al..  2014.  Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.. PloS one. 9(12):e113601. Abstract
2013
Orozco JJ, Bäck T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur SD, Fisher DR, Frayo SL, Hylarides MD, Green DJ et al..  2013.  Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.. Blood. 121(18):3759-67. Abstract
2012
Wilbur SD, Chyan M-K, Nakamae H, Chen Y, Hamlin DK, Santos EB, Kornblit BT, Sandmaier BM.  2012.  Reagents for astatination of Biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-de. Bioconjugate chemistry. 23(3):409-20. Abstract
Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur SD, Storer BE, Storb R, Sandmaier BM.  2012.  Durable donor engraftment after radioimmunotherapy using alpha-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.. Blood. 119(5):1130-1138. Abstract
2011
Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur SD, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N et al..  2011.  Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.. Blood. 118(3):703-11. Abstract
Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur SD, Stayton PS, Orgun N, Hylarides M, Buchegger F et al..  2011.  Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23):7373-82. Abstract
2010
Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur SD, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T et al..  2010.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.. Blood. 116(20):4231-9. Abstract
Nakamae H, Kerbauy FR, Wilbur SD, Bethge W, Hamlin DK, Santos EB, Storb R, Sandmaier BM.  2010.  Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation.. Transplantation. 89(11):1336-40. Abstract
Wilbur SD, Park SI, Chyan M-K, Wan F, Hamlin DK, Shenoi J, Lin Y, Wilbur SM, Buchegger F, Pantelias A et al..  2010.  Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.. Bioconjugate chemistry. 21(7):1225-38. Abstract
2009
Wilbur SD, Thakar MS, Hamlin DK, Santos EB, Chyan M-K, Nakamae H, Pagel JM, Press OW, Sandmaier BM.  2009.  Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.. Bioconjugate chemistry. 20(10):1983-91. Abstract
Pagel JM, Orgun N, Hamlin DK, Wilbur SD, Gooley TA, Gopal AK, Park SI, Green DJ, Lin Y, Press OW.  2009.  A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.. Blood. 113(20):4903-13. Abstract
Nakamae H, Wilbur SD, Hamlin DK, Thakar MS, Santos EB, Fisher DR, Kenoyer AL, Pagel JM, Press OW, Storb R et al..  2009.  Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.. Cancer research. 69(6):2408-15. Abstract
Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Hamlin DK, Wilbur SD, Fisher DR, Rajendran JG et al..  2009.  Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.. Blood. 114(6):1226-35. Abstract
2008
Pagel JM, Hedin N, Drouet L, Wood BL, Pantelias A, Lin Y, Hamlin DK, Wilbur SD, Gopal AK, Green DJ et al..  2008.  Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.. Blood. 111(4):2261-8. Abstract
Nemecek ER, Green DJ, Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack LD, Rajendran JG, Wilbur SD, Nilsson R et al..  2008.  Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.. Cancer biotherapy & radiopharmaceuticals. 23(2):181-91. Abstract
2007
Green DJ, Pagel JM, Pantelias A, Hedin N, Lin Y, Wilbur SD, Gopal A, Hamlin DK, Press OW.  2007.  Pretargeted radioimmunotherapy for B-cell lymphomas.. Clinical cancer research : an official journal of the American Association for Cancer Research. 13(18 Pt 2):5598s-5603s. Abstract
Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur SD, Gopal AK et al..  2007.  Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.. Cancer research. 67(12):5921-8. Abstract
Pantelias A, Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, Wilbur SD, Lin Y, Stone D, Axworthy D et al..  2007.  Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.. Blood. 109(11):4980-7. Abstract